FIELD: biotechnology.
SUBSTANCE: invention relates to mutant polypeptides FimH Escherichia coli and use thereof. Disclosed are versions of the mutant polypeptide FimH for inducing production of antibodies specific to uropathogenic E. coli in a subject. Also disclosed are a nucleic acid molecule coding said polypeptide, a pharmaceutical composition comprising said polypeptide or nucleic acid molecule, a recombinant mammalian cell for producing a mutant FimH polypeptide, a culture for producing the mutant FimH polypeptide, a method for producing the mutant FimH polypeptide, a method for inducing the production of uropathogenic E. coli-specific antibodies in a subject, as well as a method for preventing, treating or relieving uropathogenic E. coli infection in a subject.
EFFECT: invention provides obtaining mutant polypeptides FimH Escherichia coli with low affinity to mannoside ligands and improved biochemical properties, which provide higher functional immunogenicity compared to wild type FimH.
21 cl, 13 dwg, 24 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ESCHERICHIA COLI COMPOSITIONS AND METHODS BASED THEREON | 2021 |
|
RU2821929C1 |
| METHOD OF INCREASING IMMUNOGENICITY OF PROTEIN/PEPTIDE ANTIGEN | 2021 |
|
RU2830627C1 |
| MULTIMERIZING POLYPEPTIDES DERIVED FROM DOMAIN WITH ROLL-TYPE PENTONE BASE OF ADENOVIRUS | 2019 |
|
RU2820522C2 |
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| ANTIGENIC POLYPEPTIDES BASED ON OSPA SEQUENCE | 2019 |
|
RU2816208C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| CHLAMYDIA SP VACCINES | 2014 |
|
RU2723046C2 |
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| BOTULINUM NEUROTOXIN BIOHYBRID | 2019 |
|
RU2816855C2 |
